ADVERSE EFFECTS OF GLUCOCORTICOID THERAPY IN RHEUMATOID ARTHRITIS

Khamrayev Khamza Khamidullayevich

Khamraev Botirjon

Samarkand State Medical University Department of Internal Medicine

Abstract: *Glucocorticoids are widely used in the management of rheumatoid arthritis (RA) due to their potent anti-inflammatory and immunosuppressive properties. While these agents offer significant symptomatic relief and are often used as bridging therapy alongside disease-modifying antirheumatic drugs (DMARDs), their long-term use is associated with a broad spectrum of adverse effects. This article reviews the most common complications linked to glucocorticoid therapy in RA patients, including osteoporosis, adrenal suppression, metabolic disturbances, cardiovascular risks, ocular disorders, gastrointestinal effects, neuropsychiatric symptoms, and increased susceptibility to infections. Recognizing and managing these complications is essential to optimize patient outcomes and minimize treatment-related risks. The article emphasizes the importance of individualized therapy, dose minimization strategies, and preventive measures to reduce the burden of glucocorticoid-induced side effects.*

Keywords*: glucocorticoids, rheumatoid arthritis, side effects, osteoporosis, immunosuppression, corticosteroid therapy*

Introduction

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and varying degrees of extra-articular involvement. Glucocorticoids (GCs) have played a pivotal role in the management of RA for several decades due to their

rapid and effective anti-inflammatory and immunosuppressive actions. They are commonly used as adjunctive therapy, particularly in early stages of disease or during acute exacerbations, often in combination with disease-modifying antirheumatic drugs (DMARDs).

Despite their therapeutic efficacy, glucocorticoid use is accompanied by a wide array of adverse effects, especially when administered in high doses or for prolonged periods. These complications can affect multiple organ systems and significantly impact patients' overall health and quality of life. Common adverse effects include osteoporosis, Cushingoid features, adrenal suppression, glucose intolerance or steroid-induced diabetes, hypertension, increased infection risk, cataracts, and neuropsychiatric disorders.

Given the clinical importance of these complications, a thorough understanding of the risk profile associated with glucocorticoid therapy is essential for clinicians managing RA patients. This article aims to provide a comprehensive overview of the potential side effects of glucocorticoids in the treatment of RA and to highlight strategies for minimizing their impact through careful monitoring, dosage optimization, and preventive measures.

Materials and Methods

This article is a narrative review based on a comprehensive analysis of scientific literature related to the adverse effects of glucocorticoid therapy in rheumatoid arthritis. A systematic search was conducted using online medical databases including **PubMed**, **Scopus**, and **Google Scholar**, focusing on articles published between **2010 and 2024**. The keywords used in the search included *"glucocorticoids," "rheumatoid arthritis," "adverse effects," "steroid complications," "corticosteroid therapy,"* and *"systemic side effects."*

Only peer-reviewed articles, clinical guidelines, randomized controlled trials, systematic reviews, and meta-analyses written in English were included. Studies specifically addressing the complications and systemic side effects of glucocorticoid therapy in RA patients were selected for detailed review.

Relevant data were extracted and categorized based on the organ systems affected by glucocorticoid use, such as musculoskeletal, cardiovascular, endocrine, gastrointestinal, ocular, neurological, and immunological systems. The findings were synthesized to provide an organized overview of the clinical implications of glucocorticoid-associated adverse effects in RA management.

Results

The analysis of the selected literature revealed that glucocorticoid therapy in rheumatoid arthritis patients is consistently associated with a broad range of systemic adverse effects. These complications vary in frequency and severity depending on the dosage, duration of therapy, and individual patient susceptibility.

The most frequently reported adverse effects include:

- **Musculoskeletal Complications:**

Long-term glucocorticoid use was strongly linked to decreased bone mineral density, leading to osteoporosis and increased risk of vertebral and non-vertebral fractures. Several studies reported a 2–3-fold increase in fracture risk among chronic GC users.

- **Endocrine and Metabolic Effects:**

Adrenal suppression and iatrogenic Cushing's syndrome were observed in patients receiving prolonged GC therapy. Steroid-induced hyperglycemia and new-onset diabetes mellitus were also commonly reported, especially in high-risk individuals.

- **Cardiovascular Effects:**

Elevated blood pressure, dyslipidemia, and increased risk of atherosclerosis were noted in multiple studies. These changes contribute to a higher incidence of cardiovascular events in long-term GC users.

- **Ocular Complications:**

Cataracts (particularly posterior subcapsular type) and steroid-induced glaucoma were among the most prevalent eye-related complications documented in RA patients receiving GC therapy.

- **Gastrointestinal Effects:**

Gastric mucosal damage, peptic ulcers, and gastrointestinal bleeding were identified as significant risks, especially when glucocorticoids were combined with nonsteroidal anti-inflammatory drugs (NSAIDs).

- **Neuropsychiatric Effects:**

Mood disturbances such as anxiety, irritability, insomnia, and, in some cases, psychosis were associated with both short- and long-term GC use.

- **Immunosuppression and Infection Risk:**

Several studies emphasized the immunosuppressive effect of glucocorticoids, which increased the susceptibility to opportunistic infections including tuberculosis, fungal infections, and bacterial pneumonia.

Overall, the findings underscore the importance of carefully balancing the therapeutic benefits of glucocorticoids with their potential systemic toxicity. Preventive strategies such as dose tapering, supplementation (e.g., calcium and vitamin D), and regular monitoring are strongly recommended to mitigate these risks.

Discussion

Glucocorticoids remain an essential component in the treatment of rheumatoid arthritis (RA), particularly for achieving rapid control of inflammation and providing symptomatic relief. However, their therapeutic benefits are counterbalanced by a wide array of systemic adverse effects that can significantly compromise patient safety and quality of life, especially with long-term or high-dose use.

The findings of this review highlight that glucocorticoid-induced complications are multi-systemic in nature, affecting the musculoskeletal, endocrine, cardiovascular, gastrointestinal, ocular, neuropsychiatric, and immune systems. Among the most clinically significant effects, **osteoporosis** and subsequent fractures are consistently reported across multiple studies. This underscores the importance of bone health monitoring and the need for preventive measures such as calcium, vitamin D supplementation, and bisphosphonate therapy in patients receiving prolonged glucocorticoid treatment.

Endocrine disturbances, including adrenal suppression and steroid-induced diabetes, represent another critical challenge. These complications often go unnoticed until clinical manifestations appear, emphasizing the need for regular metabolic assessments in patients on glucocorticoid therapy. Similarly, **cardiovascular risks**, such as hypertension and atherosclerosis, further elevate the long-term morbidity in RA patients and necessitate a multidisciplinary management approach.

Moreover, **ocular side effects**, such as cataracts and glaucoma, may develop insidiously and lead to irreversible visual impairment if not promptly diagnosed. Routine ophthalmologic evaluations are thus recommended for patients on long-term therapy.

Neuropsychiatric symptoms, although less frequently emphasized, can significantly affect patient well-being and adherence to therapy. Mood changes, anxiety, insomnia, and even psychosis may require psychiatric evaluation and dose adjustments.

Importantly, the **increased susceptibility to infections**, resulting from the immunosuppressive nature of glucocorticoids, poses a serious concern, especially in elderly or comorbid patients. Vigilance for latent infections such as tuberculosis and appropriate prophylactic strategies are vital in these cases.

Despite these risks, glucocorticoids continue to play a key role in RA management. Therefore, a **risk-benefit approach** is crucial when initiating therapy. The use of the **lowest effective dose for the shortest duration possible**, along with **regular monitoring**, **preventive strategies**, and **individualized treatment plans**, can help minimize the incidence and severity of glucocorticoid-induced adverse effects.

Conclusion

Glucocorticoids play a pivotal role in the management of rheumatoid arthritis due to their rapid anti-inflammatory and immunosuppressive effects. However, their long-term use is associated with a wide spectrum of adverse effects that can affect multiple organ systems and contribute to significant morbidity. This review highlights the most commonly encountered complications, including osteoporosis, endocrine and metabolic disturbances, cardiovascular risks, ocular disorders, gastrointestinal issues, neuropsychiatric manifestations, and increased susceptibility to infections.

To optimize the therapeutic benefits while minimizing the associated risks, clinicians must adopt a balanced, patient-centered approach. This includes using

the lowest effective dose for the shortest duration possible, implementing preventive strategies such as bone protection and infection prophylaxis, and closely monitoring patients for early signs of systemic toxicity.

Ultimately, awareness and proactive management of glucocorticoid-related adverse effects are essential for improving patient outcomes and ensuring safer long-term treatment in individuals with rheumatoid arthritis.

References:

1. Van der Goes, M. C., Jacobs, J. W. G., & Bijlsma, J. W. J. (2014). Glucocorticoids in the treatment of rheumatoid arthritis. *Arthritis Research & Therapy*, *16*(Suppl 2), S1. https://doi.org/10.1186/ar4686

2. Buttgereit, F., Boers, M., Burmester, G. R., Saag, K. G., Bijlsma, J. W. J., & Kirwan, J. R. (2020). Glucocorticoids in rheumatoid arthritis: current status and future studies. *RMD Open*, *6*(2), e001347. https://doi.org/10.1136/rmdopen-2020-001347

3. Strehl, C., Bijlsma, J. W. J., de Wit, M., & Buttgereit, F. (2017). Glucocorticoid-induced osteoporosis: mechanisms, management, and prevention. *Nature Reviews Rheumatology*, *13*(5), 231–240. https://doi.org/10.1038/nrrheum.2017.26

4. Caplan, L., Wolfe, F., Russell, A. S., Michaud, K., Katz, J., & Cannon, G. W. (2017). Risk of serious infection in older adults with rheumatoid arthritis taking glucocorticoids. *Arthritis & Rheumatology*, *69*(6), 1135–1144. https://doi.org/10.1002/art.40032

5. Kirwan, J. R., Bijlsma, J. W. J., Boers, M., & Shea, B. (2007). The effect of glucocorticoids on radiological progression in rheumatoid arthritis: A meta-analysis. *Rheumatology*, *46*(4), 610–614. https://doi.org/10.1093/rheumatology/kel345

6. Fardet, L., Petersen, I., & Nazareth, I. (2007). Corticosteroid-induced adverse events in adults: Frequency, screening and prevention. *Drug Safety, 30*(10), 861–881. https://doi.org/10.2165/00002018-200730100-00006

7. Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2007). Influence of glucocorticoid therapy on mortality in patients with rheumatoid arthritis. *Arthritis & Rheumatism, 56*(3), 820–830. https://doi.org/10.1002/art.22416

8. Curtis, J. R., Westfall, A. O., Allison, J., Freeman, A., Kovac, S. H., & Saag, K. G. (2006). Population-based assessment of adverse events associated with long-term glucocorticoid use in rheumatoid arthritis. *Arthritis Care & Research, 55*(3), 420–426. https://doi.org/10.1002/art.21983

9. Schäcke, H., Döcke, W. D., & Asadullah, K. (2002). Mechanisms involved in the side effects of glucocorticoids. *Pharmacology & Therapeutics, 96*(1), 23–43. https://doi.org/10.1016/S0163-7258(02)00297-8

10. Moutsopoulos, N. M., Katsifis, G. E., & Moutsopoulos, H. M. (2019). Adverse effects of corticosteroids in autoimmune diseases: Balancing the benefits and risks. *Autoimmunity Reviews, 18*(7), 673–679.